Nachrichten zur Abbvie Inc. Aktie

Is AbbVie Still a Good Dividend Stock to Buy? @themotleyfool #stocks $ABBV

The decline in sales of Humira, AbbVies top seller, is enough to make anyone nervous.…

5 Solid Stocks to Watch That Recently Hiked Dividends

AbbVie Inc. (ABBV), Exxon Mobil Corporation (XOM), Kontoor Brands, Inc. (KTB), Select Water Solutions, Inc. (WTTR) and Macatawa Bank Corporation…

AbbVie shares rise after Barclays upgrades rating of U.S. drugmaker By Investing.com

AbbVie shares rise after Barclays upgrades rating of U.S. drugmaker…

NEXGEL announces supply agreement with AbbVie

NEXGEL (NASDAQ:NXGL) announced that its CG Converting and Packaging subsidiary has executed a supply agreement with biopharmaceutical giant AbbVie Inc to be...…

Here are Mondays biggest analyst calls: Nvidia, Tesla, Apple, AbbVie, Chevron, Krispy Kreme, Roku & more

Here are the biggest calls on Wall Street on Monday.…

Abbvie selloff overdone, says Barclays: 5 big analyst picks By Investing.com

Abbvie selloff overdone, says Barclays: 5 big analyst picks…

AbbVie gains after Barclays upgrades over clarity on top-line evolution

…

AbbVie erfüllt Erwartungen - Sanofi bestätigt Ausblick - Amazon.com-Aktie legt nach Zahlen deutlich zu

Wien (www.aktiencheck.de) - AbbVie (ISIN: US00287Y1091, WKN: A1J84E, Ticker-Symbol: 4AB, NYSE-Symbol: ABBV) konnte im dritten Quartal den Markterwartungen gerecht werden,…

Needham says Abbvies Botox sales results good news for Evolus, Revance

…

Why AbbVie Stock Fell Today @themotleyfool #stocks $ABBV

AbbVie stock fell despite beating third-quarter expectations and raising its full-year outlook. Heres what investors need to know.…

AbbVie (ABBV) Q3 2023 Earnings Call Transcript

ABBV earnings call for the period ending September 30, 2023.…

AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript

…

AbbVie: Humira Rückgang wird ausgeglichen - Aktienanalyse

Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…

Abbvie surprises in 3Q with better than expected Humira sales

Abbvie (NYSE:ABBV) raised its 2023 profit guidance after a strong quarterly earnings report driven by demand for newer drugs and…

AbbVie shares dip as revenue drops 6% from last year By Investing.com

AbbVie shares dip as revenue drops 6% from last year…

AbbVies Humira Struggles Continue, But Drugmaker Raises Outlook

Humira sales continued to decline amid a battle with new biosimilars in the U.S.…

AbbVie stock gains after guidance boost

…

AbbVie raises profit forecast after Humira, newer drugs drive results beat

AbbVie on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales…

AbbVie raises dividend by 4.7% to $1.55

…

AbbVie raises profit forecast after Humira, newer drugs drive results beat By Reuters

AbbVie raises profit forecast after Humira, newer drugs drive results beat…

AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View

AbbVies (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and…

VTV: A Must-Watch ETF for Value Investors

Value investing may not sound as exciting as investing in the next hot growth stock, but it’s a time-honored investing…

Ulcerative Colitis Market to Grow Positively by 2032, Predicts DelveInsight | Key Companies - Arena, Pfizer, Abivax, InDex, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast

With time ulcerative colitis market landscape is evolving and the treatment goals continue to shift hence the dynamics of the…

3 Biotech Stocks With Decent Dividend for a Steady Return

Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year…

AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldnt Derail Growth Plans

…

AbbVie (ABBV) to Report Q3 Earnings: Whats in the Cards?

AbbVies (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the…

The Zacks Analyst Blog Highlights Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific

Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific are included in this Analyst Blog.…

AbbVie: The Humira Loss May Be Fully Priced In After All

…

AbbVie: Q2 Success Sets The Stage For Consistent Growth

…

AbbVie Q3 Preview: Humira Weakness Is A Given But Watch The New Drugs

…

AbbVies (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with…

AbbVie hits main goal in Phase 2 trial for Rinvoq in vitiligo

…

Global Ankylosing Spondylitis Market is Projected to Reach $7.29 Billion by 2027: Leading Players Pfizer, AbbVie, and Novartis Drive Advances in Treatment Options

Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis Global Market Report 2023" report has been added…